BIOCRYST PHARMACEUTICALS, INC. Payments for Restructuring
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Payments for Restructuring of $532.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForRestructuring · last filed 2026-08-05
- BIOCRYST PHARMACEUTICALS, INC. payments for restructuring for the quarter ending 2026-06-30 was $532.00K.
- BIOCRYST PHARMACEUTICALS, INC. payments for restructuring for the quarter ending 2026-03-31 was $4.88M.
- BIOCRYST PHARMACEUTICALS, INC. payments for restructuring for the quarter ending 2024-09-30 was $291.00K.
- BIOCRYST PHARMACEUTICALS, INC. payments for restructuring for the quarter ending 2024-06-30 was $1.18M.
- BIOCRYST PHARMACEUTICALS, INC. payments for restructuring for fiscal 2025 was $836.00K, a 82.00% decline from fiscal 2024.
- BIOCRYST PHARMACEUTICALS, INC. payments for restructuring for fiscal 2024 was $4.64M.
- BIOCRYST PHARMACEUTICALS, INC. payments for restructuring for fiscal 2013 was $1.60M, a 2665.52% increase from fiscal 2012.
- BIOCRYST PHARMACEUTICALS, INC. payments for restructuring for fiscal 2012 was $58.00K.
| Period end | Payments for Restructuring 3 month | Payments for Restructuring 4 month | Payments for Restructuring 6 month | Payments for Restructuring 7 month | Payments for Restructuring 9 month | Payments for Restructuring 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $532.00K 10-Q · filed 2026-08-05 | $5.41M derived: sum of 2 quarters · filed 2026-08-05 | $6.25M 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | $4.88M 10-Q · filed 2026-08-05 | $5.72M 10-Q · filed 2026-05-06 | ||||
| 2025-12-31 | $836.00K 10-K · filed 2026-02-26 | |||||
| 2024-12-31 | $4.64M 10-K · filed 2026-02-26 | |||||
| 2024-09-30 | $291.00K 10-Q · filed 2024-11-05 | $1.47M derived: sum of 2 quarters · filed 2024-11-05 | $4.64M derived: sum of 3 quarters · filed 2024-11-05 | |||
| 2024-06-30 | $1.18M 10-Q · filed 2024-11-05 | $4.35M derived: sum of 2 quarters · filed 2024-11-05 | ||||
| 2024-03-31 | $3.17M 10-Q · filed 2024-11-05 | |||||
| 2013-12-31 | $95.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $174.00K derived: sum of 2 quarters · filed 2015-03-02 | $1.60M 10-K · filed 2015-03-02 | |||
| 2013-09-30 | $79.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | $1.51M 10-Q · filed 2013-11-08 | ||||
| 2013-06-30 | $1.43M 10-Q · filed 2013-08-08 | |||||
| 2012-12-31 | $58.00K 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |